Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02040857
Title A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute|Pfizer
Indications

breast cancer

Her2-receptor negative breast cancer

Therapies

Exemestane

Palbociclib

Tamoxifen

Letrozole

Anastrozole

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Francisco San Francisco California 94115 United States Details
Indiana University Health Hospital Indianapolis Indiana 46202 United States Details
Massachusetts General Hospital Boston Massachusetts 02214 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
MGH/North Shore Cancer Center Danvers Massachusetts 01923 United States Details
DF/DWCC at Milford Regional Cancer Center Milford Massachusetts 01757 United States Details
South Shore Hospital Weymouth Massachusetts 02190 United States Details
Dana-Farber/New Hampshire Oncology-Hematology Londonderry New Hampshire 03053 United States Details
University of Pennsylvania-Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field